AstraZeneca
rare disease new phase trial starts with blockbuster potential alfa first in class with potential to reverse the course of disease population | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
February 2024
Slide
26 of 45
Related slides by other companies
Equillium
Investor Presentation
August 2023
clinically validated in severe dermatological disease | Equillium
Equillium
Investor Presentation
December 2023
clinically validated in severe dermatological disease | Equillium
BioNTech
Results
November 2020
phase a safety profile | BioNTech
Exscientia
Results
March 2024
elucidate phase ongoing in advanced solid | Exscientia
Other recent decks by AstraZeneca
See all presentations (27 decks)
Investor Conference
January 2024
Results
November 2023
Results
July 2023
Investor Event
June 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io